Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMariscal, Anaís
dc.contributor.authorMilán, Milena
dc.contributor.authorBaucells, Andrés
dc.contributor.authorMartínez, Maria Angeles
dc.contributor.authorGarcia Guillen, Andrea
dc.contributor.authorTrallero Araguas, Ernesto
dc.contributor.authorAlvarado-Cardenas, Marcelo
dc.contributor.authorSanz Martinez, Maria Teresa
dc.contributor.authorViñas Gimenez, Laura
dc.contributor.authorSelva O'Callaghan, Albert
dc.date.accessioned2022-01-24T14:22:29Z
dc.date.available2022-01-24T14:22:29Z
dc.date.issued2021-02-01
dc.identifier.citationMariscal A, Milán M, Baucells A, Martínez MA, Guillen AG, Trallero-Araguás E, et al. Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice. Front Immunol. 2021 Feb 1;11:3672.
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/11351/6881
dc.descriptionCancer; Dermatomyositis; Immunoassay
dc.description.abstractObjectives: Anti-TIF-1γ autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1γ detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1γ. Methods: We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebrón Hospital (Barcelona, Spain) tested for anti-TIF-1γ autoantibodies using the Euroline profile and an in-house immunoblot assay. Results: A total of 27 anti-TIF-1γ were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen’s kappa 0.3163. Expected prevalence of anti-TIF-1γ autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1γ autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1γ antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). Conclusion: We recommend using a second validated method to confirm Euroline-detected anti-TIF-1γ antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1γ antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Immunology;11
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectDermatomiositis - Diagnòstic
dc.subjectAutoanticossos - Immunologia
dc.subject.meshDermatomyositis
dc.subject.mesh/diagnosis
dc.subject.meshAutoantibodies
dc.subject.mesh/immunology
dc.titleAnti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fimmu.2020.625896
dc.subject.decsdermatomiositis
dc.subject.decs/diagnóstico
dc.subject.decsautoanticuerpos
dc.subject.decs/inmunología
dc.relation.publishversionhttps://doi.org/10.3389/fimmu.2020.625896
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Mariscal A, Baucells A, Martínez MA] Immunology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain. [Milán M, Guillen AG] Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain. [Trallero-Araguás E] Unitat de Reumatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Alvarado-Cardenas M] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Sanz-Martínez MT, Viñas-Giménez L] Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Selva-O'Callaghan A] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid33613568
dc.identifier.wos000619602500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record